Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ibio Inc IBIO

Healthcare Biotechnology
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu... see more

Recent & Breaking News (NYSEAM:IBIO)

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

GlobeNewswire March 27, 2024

iBio Announces $15.0 Million Private Placement

GlobeNewswire March 26, 2024

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

GlobeNewswire February 26, 2024

iBio Announces Participation in 23rd Annual PepTalk Conference

GlobeNewswire January 16, 2024

iBio Amends and Extends Maturity of Credit Agreement

GlobeNewswire December 26, 2023

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

GlobeNewswire December 5, 2023

iBio Announces Reverse Stock Split

GlobeNewswire November 27, 2023

iBio Further Expands Tech Stack with ShieldTx(TM); Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

GlobeNewswire November 1, 2023

iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics

GlobeNewswire October 10, 2023

iBio Explains Recent Filing of Registration Statement

GlobeNewswire October 2, 2023

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

GlobeNewswire September 27, 2023

iBio Announces Amendment to Credit Agreement with Woodforest

GlobeNewswire September 21, 2023

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

GlobeNewswire August 14, 2023

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

GlobeNewswire June 27, 2023

iBio Forges Research Collaboration with the National Institutes of Health

GlobeNewswire June 12, 2023

iBio Expands Tech Stack with EngageTx(TM); Adds TROP-2 Bispecific to Development Pipeline

GlobeNewswire June 6, 2023

iBio to Participate in the JMP Securities Life Sciences Conference

GlobeNewswire May 9, 2023

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

GlobeNewswire April 4, 2023

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

GlobeNewswire March 31, 2023

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

GlobeNewswire February 16, 2023